How to read an FDA complete response letter

A drug or biologic review does not always end with an approval letter. When FDA finishes reviewing an NDA or BLA and cannot approve it as submitted, it sends a Complete Response Letter (CRL) instead — a formal, dense document that is easy to misread as either a flat rejection or a full accounting of everything wrong with the application. It is usually neither, and reading one well means knowing what it is actually built to do.

What the letter actually does

A CRL states the grounds FDA relied on for not approving the application and, where practical, describes what the applicant would need to address to put the application in condition for approval — without guaranteeing that doing so will be sufficient. It replaces what were once separate “approvable” and “not approvable” letter categories with a single unified action, and it is worth reading as exactly that: a statement of what stood between this application and approval on this review cycle, not a comprehensive audit of the product.

Why you rarely see the actual document

FDA does not publish complete response letters the way it publishes warning letters or, on the device side, De Novo classification orders — both of which live in public FDA databases. A CRL's contents become public only if the sponsor discloses them, which for publicly traded companies is often driven by securities disclosure obligations rather than any FDA transparency requirement. What actually circulates after a CRL is usually a press release characterizing the letter, not the letter itself — and reading a company's characterization of a regulatory document is a meaningfully different skill from reading the document, worth keeping distinct in your own head even when it is the only version available to you.

The two kinds of resubmission

Not every CRL requires new clinical data to resolve. FDA and the sponsor typically work out, early in the process, whether the deficiencies can be addressed without new studies — a shorter review on resubmission — or whether they require new data, which puts the resubmission on a longer clock. That classification is a matter of FDA practice and correspondence with the review division, not something the letter always states in so many words, which is one more reason a CRL is a starting point for a conversation with your review division rather than a self-contained instruction manual.

If you are moving into pharma regulatory work from a device background, a CRL is one of the first documents worth understanding on its own terms — it does not have a device-side equivalent, and the instinct to expect a public, FDA-published version of it will lead you to the wrong place to look.